
## Maurizio Bussotti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8866012/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Sexual and Reproductive Health in Women with Pulmonary Hypertension: A Qualitative Study. Archives of Sexual Behavior, 2022, 51, 1647-1657.	1.2	7
2	Old and new equations for maximal heart rate prediction in patients with heart failure and reduced ejection fraction on beta-blockers treatment: results from the MECKI score data set. European Journal of Preventive Cardiology, 2022, 29, 1680-1688.	0.8	11
3	Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial. European Heart Journal, 2021, 42, 2284-2295.	1.0	51
4	Effects of an outpatient service holistic rehabilitation program in a case of pulmonary atresia. Monaldi Archives for Chest Disease, 2021, 91, .	0.3	0
5	Evidence for Biological Age Acceleration and Telomere Shortening in COVID-19 Survivors. International Journal of Molecular Sciences, 2021, 22, 6151.	1.8	62
6	The Future of Exercise-Based Cardiac Rehabilitation for Patients With Heart Failure. Frontiers in Cardiovascular Medicine, 2021, 8, 709898.	1.1	14
7	Gender and age normalization and ventilation efficiency during exercise in heart failure with reduced ejection fraction. ESC Heart Failure, 2020, 7, 368-377.	1.4	23
8	Role of gender, age and BMI in prognosis of heart failure. European Journal of Preventive Cardiology, 2020, 27, 46-51.	0.8	47
9	Long-term prognostic role of diabetes mellitus and glycemic control in heart failure patients with reduced ejection fraction. International Journal of Cardiology, 2020, 317, 103-110.	0.8	13
10	Cardiovascular Death Risk in Recovered Mid-Range Ejection Fraction Heart Failure: Insights From Cardiopulmonary Exercise Test. Journal of Cardiac Failure, 2020, 26, 932-943.	0.7	8
11	Standardised exercise training is feasible, safe and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension - results from a large European multicentre randomised controlled trial. , 2020, , .		0
12	Residential cardiac rehabilitation (rCR) derived survival predictors in patients after transcatheter aortic valve replacement (TAVR): a retrospective multicenter study. European Heart Journal, 2020, 41, .	1.0	0
13	<p>Non-vitamin K oral anticoagulant use in the elderly: a prospective real-world study – data from the REGIstry of patients on Non-vitamin K oral Anticoagulants (REGINA)</p> . Vascular Health and Risk Management, 2019, Volume 15, 19-25.	1.0	23
14	Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and midâ€range ejection fraction. European Journal of Heart Failure, 2019, 21, 1586-1595.	2.9	24
15	Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years. European Journal of Heart Failure, 2019, 21, 208-217.	2.9	60
16	Improvement of hypoxemia in patients affected by Pulmonary Arterial Hypertension (PAH) after a session of Controlled Breathing (CB). , 2019, , .		0
17	Mineralocorticoid receptor antagonists for heart failure: a realâ€life observational study. ESC Heart Failure, 2018, 5, 267-274.	1.4	13
18	Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a longâ€ŧerm comparison. European Journal of Heart Failure, 2018, 20, 700-710.	2.9	84

MAURIZIO BUSSOTTI

#	Article	IF	CITATIONS
19	Exercise training in pulmonary arterial hypertension. Journal of Thoracic Disease, 2018, 10, 508-521.	0.6	26
20	Anxiety and depression in patients with pulmonary hypertension: impact and management challenges. Vascular Health and Risk Management, 2018, Volume 14, 349-360.	1.0	48
21	Dose-dependent efficacy of β-blocker in patients with chronic heart failure and atrial fibrillation. International Journal of Cardiology, 2018, 273, 141-146.	0.8	13
22	Exercise Prescription in Patients with Different Combinations of Cardiovascular Disease Risk Factors: A Consensus Statement from the EXPERT Working Group. Sports Medicine, 2018, 48, 1781-1797.	3.1	126
23	High Altitude Pulmonary Hypertension. Cardiovascular & Hematological Disorders Drug Targets, 2018, 18, 187-198.	0.2	9
24	Prognostic role of βâ€blocker selectivity and dosage regimens in heart failure patients. Insights from the <scp>MECKI</scp> score database. European Journal of Heart Failure, 2017, 19, 904-914.	2.9	28
25	The European Association of Preventive Cardiology Exercise Prescription in Everyday Practice and Rehabilitative Training (EXPERT) tool: A digital training and decision support system for optimized exercise prescription in cardiovascular disease. Concept, definitions and construction methodology. European lournal of Preventive Cardiology, 2017, 24, 1017-1031.	0.8	141
26	Heart failure and anemia: Effects on prognostic variables. European Journal of Internal Medicine, 2017, 37, 56-63.	1.0	33
27	Effects of an Outpatient Service Rehabilitation Programme in Patients Affected by Pulmonary Arterial Hypertension: An Observational Study. Cardiovascular & Hematological Disorders Drug Targets, 2017, 17, 3-10.	0.2	20
28	Exercise tolerance can explain the obesity paradox in patients with systolic heart failure: data from the <scp>MECKI</scp> Score Research Group. European Journal of Heart Failure, 2016, 18, 545-553.	2.9	64
29	Exercise Performance Is a Prognostic Indicator in Elderly Patients With Chronic Heart Failure – Application of Metabolic Exercise Cardiac Kidney Indexes Score –. Circulation Journal, 2015, 79, 2608-2615.	0.7	21
30	Renal Function and Peak Exercise Oxygen Consumption in Chronic Heart Failure With Reduced Left Ventricular Ejection Fraction. Circulation Journal, 2015, 79, 583-591.	0.7	29
31	Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trial. International Journal of COPD, 2015, 10, 1917.	0.9	35
32	Impact of chronic obstructive pulmonary disease on exercise ventilatory efficiency in heart failure. International Journal of Cardiology, 2015, 189, 134-140.	0.8	66
33	Deceptive meaning of oxygen uptake measured at the anaerobic threshold in patients with systolic heart failure and atrial fibrillation. European Journal of Preventive Cardiology, 2015, 22, 1046-1055.	0.8	32
34	Respiratory disorders in endurance athletes – how much do they really have to endure?. Open Access Journal of Sports Medicine, 2014, 5, 47.	0.6	15
35	Noninvasive Cardiac Output Measurement by Inert Gas Rebreathing in Suspected Pulmonary Hypertension. American Journal of Cardiology, 2014, 113, 546-551.	0.7	27
36	Acute high-altitude exposure reduces lung diffusion: Data from the HIGHCARE Alps project. Respiratory Physiology and Neurobiology, 2013, 188, 223-228.	0.7	42

MAURIZIO BUSSOTTI

#	Article	IF	CITATIONS
37	Highâ€altitude hypoxia and periodic breathing during sleep: genderâ€related differences. Journal of Sleep Research, 2013, 22, 322-330.	1.7	82
38	Lungs in Heart Failure. Pulmonary Medicine, 2012, 2012, 1-9.	0.5	34
39	Exercise testing in the clinical management of patients affected by pulmonary arterial hypertension. European Journal of Preventive Cardiology, 2012, 19, 960-971.	0.8	55
40	Chronotropic Incompentence and Functional Capacity in Chronic Heart Failure: No Role of <i>β</i> â€Blockers and <i>β</i> â€Blocker Dose. Cardiovascular Therapeutics, 2012, 30, 100-108.	1.1	45
41	Effects of Slow Deep Breathing at High Altitude on Oxygen Saturation, Pulmonary and Systemic Hemodynamics. PLoS ONE, 2012, 7, e49074.	1.1	51
42	Effects of carvedilol on oxygen uptake and heart rate kinetics in patients with chronic heart failure at simulated altitude. European Journal of Preventive Cardiology, 2012, 19, 444-451.	0.8	3
43	High-altitude exposure of three weeks duration increases lung diffusing capacity in humans. Journal of Applied Physiology, 2011, 110, 1564-1571.	1.2	45
44	Continuous positive airway pressure increases haemoglobin O2 saturation after acute but not prolonged altitude exposure. European Heart Journal, 2010, 31, 457-463.	1.0	26
45	Effects of $\hat{I}^2$ -blockers on ventilation efficiency in heart failure. American Heart Journal, 2010, 159, 1067-1073.	1.2	42
46	Circulating Plasma Surfactant Protein Type B as Biological Marker of Alveolar-Capillary Barrier Damage in Chronic Heart Failure. Circulation: Heart Failure, 2009, 2, 175-180.	1.6	32
47	"Beyond the ventilation†a reply to the letter to the editor of A. M. Ferrazza and P. Palange. European Journal of Applied Physiology, 2009, 105, 979-980.	1.2	Ο
48	Do Maximum Flow-Volume Loops Collected During Maximum Exercise Test Alter the Main Cardiopulmonary Parameters?. Chest, 2009, 135, 425-433.	0.4	14
49	End-tidal pressure of CO2 and exercise performance in healthy subjects. European Journal of Applied Physiology, 2008, 103, 727-732.	1.2	25
50	Sildenafil improves the alveolar–capillary function in heart failure patients. International Journal of Cardiology, 2008, 126, 68-72.	0.8	14
51	Lung function with carvedilol and bisoprolol in chronic heart failure: Is β selectivity relevant?. European Journal of Heart Failure, 2007, 9, 827-833.	2.9	54
52	Cardiopulmonary interaction in heart failure. Pulmonary Pharmacology and Therapeutics, 2007, 20, 130-134.	1.1	37
53	Carvedilol reduces exercise-induced hyperventilation: A benefit in normoxia and a problem with hypoxia. European Journal of Heart Failure, 2006, 8, 729-735.	2.9	48
54	Cardiopulmonary evidence of exercise-induced silent ischaemia. European Journal of Cardiovascular Prevention and Rehabilitation, 2006, 13, 249-253.	3.1	21

MAURIZIO BUSSOTTI

#	Article	IF	CITATIONS
55	Gas diffusion and alveolar-capillary unit in chronic heart failure. European Heart Journal, 2006, 27, 2538-2543.	1.0	209
56	Lateral Decubitus Position Generates Discomfort and Worsens Lung Function in Chronic Heart Failure. Chest, 2005, 128, 1511-1516.	0.4	20
57	Impaired bradykinin response to ischaemia and exercise in patients with mild congestive heart failure during angiotensin-converting enzyme treatment. Relationships with endothelial function, coagulation and inflammation. British Journal of Haematology, 2005, 130, 113-120.	1.2	16
58	Exercise capacity in patients with beta-thalassaemia intermedia. British Journal of Haematology, 2005, 131, 278-281.	1.2	12
59	Work-rate affects cardiopulmonary exercise test results in heart failure. European Journal of Heart Failure, 2005, 7, 498-504.	2.9	99
60	Spironolactone improves lung diffusion in chronic heart failure. European Heart Journal, 2005, 26, 159-164.	1.0	66
61	Exercise-induced changes in exhaled nitric oxide in heart failure. European Journal of Heart Failure, 2004, 6, 551-554.	2.9	8
62	Exhaled Nitric Oxide and Exercise Performance in Heart Failure. Archives of Physiology and Biochemistry, 2003, 111, 293-296.	1.0	3
63	Does lung diffusion impairment affect exercise capacity in patients with heart failure?. British Heart Journal, 2002, 88, 453-459.	2.2	48
64	Carvedilol Reduces the Inappropriate Increase of Ventilation During Exercise in Heart Failure Patients. Chest, 2002, 122, 2062-2067.	0.4	72
65	Effects of simulated altitude-induced hypoxia on exercise capacity in patients with chronic heart failure. American Journal of Medicine, 2000, 109, 450-455.	0.6	69
66	Cardiomegaly as a possible cause of lung dysfunction in patients with heart failure. American Heart Journal, 2000, 140, A17-A21.	1.2	58
67	Lack of improvement of lung diffusing capacity following fluid withdrawal by ultrafiltration in chronic heart failure. Journal of the American College of Cardiology, 2000, 36, 1600-1604.	1.2	75
68	Impeded Alveolar-Capillary Gas Transfer With Saline Infusion in Heart Failure. Hypertension, 1999, 34, 1202-1207.	1.3	42
69	Evidence of Multifocal Activity of Coronary Disease in Patients With Acute Myocardial Infarction. Circulation, 1997, 96, 1145-1151.	1.6	47